“After many failures in the last 12 years, the combination of [atezolizumab] and [bevacizumab] shows improvement in OS compared to sorafenib and offers patients the opportunity for improved disease control with high ORR.” In May 2020, the FDA approved atezolizumab plus bevacizumab for the trea...
近日,FDA批准了基因泰克(Genentech)开发的atezolizumab(Tecentriq)+bevacizumab(Avastin)联合免疫疗法,用于无法切除或转移性肝细胞癌(HCC)患者的一线治疗。这也是FDA批准的无法切除或转移性肝细胞癌的首个一线免疫治疗方案,引起了很大的关注。 首先...
Atezolizumab plus bevacizumab is currently the main choice of first-line treatment for unresectable hepatocellular carcinoma(HCC),which has been proven superior to sorafenib for overall survival(OS)and progression-free survival(PFS)in the phase III IMbrave150 trial(1).Up-data analysis from IMbrave150...
“Safety of combined atezolizumab plus bevacizumab was consistent with the known safety profile of each agent alone; further follow-up showed no new safety signals,” Powles commented. Both atezolizumab and bevacizumab were more well-tolerated than sunitinib. Treatment related serious adverse events (A...
Journal of Hepatocellular Carcinoma Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >...
(uHCC) more in the first-line setting remains controversial.Objective In this analysis, we compared the clinical outcomes of lenvatinib monotherapy with atezolizumab plus bevacizumab combination therapy in advanced uHCC in real-world clinical... BC Wang,BH Kuang,GH Lin - 《Targeted Oncology》 被引...
(HealthDay)—For patients with metastatic renal cell carcinoma (mRCC), atezolizumab plus bevacizumab is associated with a progression-free survival benefit versus sunitinib, according to a study presented at the American Society of Clinical Oncology's an
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezolizumab Plus Bevacizumab Compared With Placebo Plus Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated With Systemic Therapy ...
Stacey Stein, MD, discusses the patient population and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma. This is a modal window. The Playback API request failed for an unknown reason Error Code: VIDEO_CLOUD_ERR_UNKNOWN Technical ...
The China National Medical Products Administration has approved the combination of atezolizumab plus bevacizumab for use in patients with unresectable hepatocellular carcinoma who have not received previous systemic therapy. Levi Garraway, MD, PhD